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ABSTRACT
Development of efficient and cost-effective manufacturing routes towards HIV active pharmaceutical 
ingredients (APIs) is essential to ensure their global, affordable access. Continuous pharmaceutical 
manufacturing (CPM) is a new production paradigm for the pharmaceutical industry, whose potential 
for enhanced efficiency and economic viability over currently implemented batch protocols offers 
promise for improving HIV API production. Nevirapine is a widely-prescribed HIV API, whose 
continuous flow synthesis was recently demonstrated. This paper presents technoeconomic optimisation 
of nevirapine CPM, including the continuous flow synthesis and a conceptual continuous crystallisation. 
Arrhenius law parameter estimation from published reaction kinetic data allows explicit modelling of 
the temperature-dependence of reaction performance and an experimentally validated aqueous API 
solubility computation method is used to model crystallisation processes. A nonlinear optimisation 
problem for cost minimisation is formulated for comparative evaluation of different plant designs. 
Higher reactor temperatures are favoured for CPM total cost minimisation, while lower pH (less 
neutralising agent) is required to attain the desired plant capacities for cost optimal configurations 
compared to batch crystallisation designs. Suitable E-factors for pharmaceutical manufacturing are 
attained when higher solvent recoveries are assumed. Implementing CPM designs significantly lowers 
the nevirapine cost of goods towards reducing the price of societally-important HIV medicines.
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11. Introduction
Affordability and accessibility of essential medicines remains a pressing issue for the treatment of 
diseases prevalent in developing countries. The treatment of the human immunodeficiency virus (HIV) 
continues to be one of the most prominent global health challenges; the prevalence of the virus has been 
historically increasing worldwide, with low- and middle-income countries being those most affected 
(Fig. 1). The development of efficient, cost-effective manufacturing routes towards drugs for HIV 
treatment is paramount to ensure global, affordable access to such medicines.1
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Figure 1: Increasing worldwide HIV prevalence2 and the top 20 countries with the highest viral rates.3
Continuous pharmaceutical manufacturing (CPM) has emerged as a new production paradigm for its 
promise of enhanced efficiency and greater economic viability over currently implemented batch 
protocols.4,5 The utility of CPM platforms for the development of active pharmaceutical ingredients 
(APIs) for the treatment of HIV and other societally-important diseases, has been demonstrated in the 
literature;6,7 Table 1 lists various HIV APIs whose syntheses have benefited by implementing semi-
continuous/continuous flow methods.  While experimental demonstration of feasible API continuous 
synthetic routes is the foundation of any CPM campaign,7,8 the design of continuous separation 
processes for integration into upstream CPM is essential to realise the benefits of end-to-end continuous 
manufacturing for HIV API production.9
Table 1: Demonstrated continuous/semi-continuous flow syntheses of HIV APIs.
API Year Continuous / Semi-Continuous Processing Benefits Ref.
Improved API yield
Reduced process timeEfavirenz 2013 Semi-continuous Reduced number of 
unit operations
33
Darunavir 2015 Continuous End-to-end continuous process at production scale 34, 35
Improved API yieldLamivudine 2017 Semi-continuous Reduced process time 36
Improved material efficiency
Nevirapine 2017 Continuous Reduced number of 
unit operations
10
Dolutegravir 2018 Continuous Reduced process time 37
Nevirapine is a widely-prescribed API for HIV-1 treatment on the World Health Organisation 
(WHO) List of Essential Medicines, whose continuous flow synthesis from two advanced starting 
materials was recently demonstrated with subsequent purification and batch crystallisation for final API 
separation.10 Additionally, various routes towards one of the API synthesis starting materials, 2-chloro-
3-amino-4-picoline (CAPIC), has also been presented in the literature.11,12 The economic viability of 
different process alternatives for the API is yet to be systematically investigated and is essential to 
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2ensure cost optimal designs. Systematic comparison of process alternatives is essential to further aid 
the development of leaner manufacturing routes towards this societally-important HIV API.13 
Process modelling and optimisation methodologies can be used to establish optimal design 
configurations.13,14 Advanced theoretical methods have been previously implemented towards optimal 
pharmaceutical unit design15 and optimisation of pharmaceutical manufacturing processes to elucidate 
optimal operation, analysis of synthetic pathways16–18 and life-cycle assessments.19,20 Modelling and 
optimisation have also been implemented in the design of separation processes in pharmaceutical 
manufacturing, such as liquid-liquid extraction (LLE),21–23 crystallisation24–30 and chromatographic 
methods.31 Identification of cost optimal plantwide designs is essential,15 particularly end-to-end 
designs encompassing synthesis and purification/separation. Elucidating cost optimal designs for 
nevirapine CPM will further aid process development for this societally-important API.5,32
This work conducts a systematic comparative evaluation of CPM process alternatives for nevirapine 
based upon the published synthetic routes via steady-state process modelling and optimisation.10–12 The 
continuous process for nevirapine demonstrated in the literature are first presented. A conceptual 
continuous crystallisation process is considered for comparison to the demonstrated batch 
crystallisation process. Arrhenius parameter estimation from experimental kinetic data allows flow 
reactor design for the continuous synthesis of nevirapine. Crystallisation process design utilises an 
established API solubility model.38 Costing methodologies for pharmaceutical process alternatives are 
presented.5 A constrained nonlinear optimisation problem for total cost minimisation of different design 
alternatives is then formulated. Optimal total cost components, plant material efficiencies and 
corresponding operating parameters are presented for different process configurations for comparative 
evaluation to establish the most promising designs for nevirapine production.
2. Process Modelling, Simulation and Optimisation
2.1 API and Starting Material Synthetic Routes
Various commercial routes towards nevirapine have been demonstrated in the literature with varying 
complexities and material intensities.39 The recent demonstration of the continuous flow synthesis of 
nevirapine uses advanced starting materials, 2-chloro-3-amino-4-picoline (CAPIC) and MeCAN (2-
(cyclopropylamino)nicotinate).10 The syntheses of CAPIC and MeCAN are summarised below (Fig. 2).
Fig. 2a illustrates the published batchwise synthesis of CAPIC. Acetone and malononitrile (2) react 
in toluene (PhMe) in the presence of basic Al2O3 at 15-20 °C to form ylidene (3), followed by filtration 
of Al2O3 from the reaction mixture. Dimethyl formamide-dimethyl-sulfate (DMF-DMS, 4) and acetic 
anhydride (Ac2O) and triethylamine (TEA) are then added to the filtrate under N2 to form enamine (5). 
Hydrogen chloride (HCl) gas is then bubbled into the reaction mixture and heated to 50 °C. The mixture 
is then concentrated by evaporating solvent and water followed by filtration of product 2-chloro-4-
methylnicotinonitrile (CYCIC, 6). Sulfuric acid (H2SO4) is then added to the solid CYCIC and reacted 
at high temperature followed by the addition of water. An aqueous solution of NaOH is added at 40 °C 
until pH = 11. The resulting suspension is then filtered for product 2-chloro-4-methylnicotinamide 
(COMAD, 7). A mixture of COMAD, water and sodium hypobromite (NaOBr) is made at 0 °C. Water 
is then added and the mixture is heated to 80 °C and stirred. After cooling to 50 °C, PhMe is added to 
form a biphasic mixture; the organic layer is washed with water and concentrated under vacuum to 
remove solvent. Hexanes are then added to precipitate CAPIC.
Fig. 2b illustrates the published batchwise synthesis of MeCAN. 2-chloronicotinonitrile (9), 
cyclopropylamine (CPA), TEA, water and isopropyl alcohol (IPA) are added at 140 °C and pressurised 
to 10 psi to form intermediate 10. The mixture is stirred and then cooled to 60 °C. Potassium hydroxide 
(KOH) is then added to the reaction mixture and stirred. Concentrated HCl is added to change pH to 6 
and cooled to 10 °C to precipitate 2-(cyclopropylamino)nicotinic acid (2-CAN, 11), which is then 
vacuum filtered. 2-CAN is then dissolved in PhMe under N2, adding thionyl chloride (SOCl2). The 
reaction mixture is cooled to 0 °C followed by H2O addition and pH adjusted to 9 with NaOH solution 
(aq.) and a biphasic mixture forms. The aqueous layer is washed with PhMe and the combined organic 
layers washed with H2O and dried with Mg2SO4, followed by filtration and concentrated under vacuum 
to yield MeCAN.
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2-CAN
(11)
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(12)
r.t. r.t.
Al2O3
PhMe, 20 °C
+ +
TEA, Ac2O
PhMe, r.t.
HCl (g)
PhMe, 5-55 °C 5-105 °C H2O, 0-80 °C
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(2)
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Figure 2: Published batchwise syntheses of (a) CAPIC and (b) MeCAN.10
The published continuous synthetic route from CAPIC and MeCAN is shown in Fig. 3.10 Starting 
materials CAPIC and MeCAN (in diglyme carrier solvent) are used to form intermediate N-(2-chloro-
4-methylpyridin-3-yl)-2-(cyclopropylamino)nicotinamide (CYCLOR) in the presence of NaH, which 
then forms nevirapine (API). The CPM process in this work is based upon this demonstrated continuous 
flow synthesis; whose process modelling and simulation are further developed in later sub-sections.
Name: CAPIC
2-chloro-3-amino-
4-picoline
MeCAN
methyl 2-(cyclopropyl-
amino)nicotinate
API
Nevirapine
Type: Reagent Reagent Product
MW (g mol-1): 142.59 192.21 266.30
Formula: C6H7ClN2 C10H12N2O2 C15H14N4O
+
CYCLOR
N-(2-chloro-4-methylpyridin-3-yl)-
2-(cyclopropylamino)nicotinamide
Intermediate
192.21
C10H12N2O2
NaH
Diglyme,
65-95 °C 
NaH
Diglyme
Figure 3: Nevirapine continuous synthetic strategy from CAPIC and MeCAN.10 
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42.2 Process Flowsheets
Fig. 4 shows the process flowsheet for nevirapine CPM based on the published continuous flow 
synthesis.10 The first reactor, R-101, is a thin-film reactor operated at 95 °C; reaction between CAPIC 
(3 M) and NaH (2 M) in diglyme at 95 °C forms the sodium salt of CAPIC (CAPIC-Na) with evolution 
of H2 gas and an estimated 100% conversion of CAPIC. The mixture containing CAPIC-Na is added to 
a stirred tank (R-102, 65 °C) with neat MeCAN (1.05 eq.) with 82.5% conversion of CAPIC-Na to 
CYCLOR (+ sodium methoxide, NaCH3O) reported. Finally, CYCLOR undergoes ring closure in the 
presence of a packed bed of NaH (R-103) to form nevirapine (API). The subsequent crystallisation can 
be performed in batch or continuous mode. Various reaction performances at different temperatures 
(TR103) are reported in the demonstrated continuous flow synthesis,10 discussed further in section 2.3.1.3.
R-101 CAPIC + NaH CAPIC-Na + H2(g)
Diglyme, 95 °C
CAPIC-Na + MeCAN CYCLOR + Na+CH3O-R-102
Diglyme, 65 °C
R-103 CYCLOR API + HCl
Diglyme, TR103 °C
NaH
CAPIC
Diglyme
NaH
MeCAN
R-101
(95 °C)
R-102
(65 °C) Crystallisation API
Waste
R-103
(TR103 °C)
Figure 4: Process flowsheet for the CPM of nevirapine.
The flowsheet for the crystallisation process following the continuous flow synthesis is shown in Fig. 
5. The effluent of R-103 is feed to a stirred tank where aqueous HCl is added; the API is more soluble 
at lower pH in aqueous solutions. Activated carbon (AC) is also added to adsorb organic impurities 
prior to their subsequent removal via filtration.10 Nevirapine (API) is then crystallised from solution by 
decreasing the API solubility by increasing pH by addition of aqueous NaOH solution. The 
crystallisation following the continuous flow synthesis can be either implemented in batch (BX) or 
continuous (CPM) mode. Details of crystallisation modelling are provided in section 2.3.2.
HCl (aq.)
Feed
AC NaOH (aq.)
API
Waste
Purification Filtration Crystallisation
Figure 5: Crystallisation of API operated in batch (BX) or continuous (CPM) mode.10
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52.3 Modelling and Nonlinear Optimisation
2.3.1 Reactor Design and Kinetic Parameter Estimation
Plantwide mass balances are required for detailed unit operation modelling and plantwide performance 
analysis. Molar balances across each reactor are calculated via eq. 1.
F ji  =  F jA,0(Θ ji  +  ν ji X jA) (1)
Here, Fij is the molar flowrate of component i exiting reactor j, FA,0j is the inlet molar flowrate of limiting 
reagent A in reactor j, Θij is the molar ratio of component i to limiting reagent A in reactor j, νij is the 
stoichiometric coefficient of component i in reactor j and XAj is the conversion of limiting reagent A in 
reactor j. Modelling and design of each reactor in the process flowsheet (Fig. 3) is now discussed. Fixed 
process conditions for each of the three reactors required are summarised in Table 2.
Table 2: Summary of continuous flow reactor conditions used in process modelling.
Reactor Reaction Temperature, T (°C) τ (units) XA (%)
R-101 CAPIC + NaH → CAPIC-Na 95 8.56 (s) 100
R-102 CAPIC-Na + MeCAN → CYCLOR 65 2 (hr) 82.5
R-103 CYCLOR → API Variable 21 (min) XAR103 = f (TR103)
2.3.1.1 Reactor R-101
Full conversion of CAPIC to CAPIC-Na (XAR101 = 100%) is reported for a R-101 operating temperature 
of 95 °C and an estimated residence time of 8.56 s; this stoichiometric conversion in a short residence 
time is allowed by implementing a thin-film reactor to enhance and heat and mass transfer to expedite 
the reaction.10 The operating temperature of R-101 is chosen to be the same as in the published 
experimental demonstration (TR101 = 95 °C); thus, the same reaction performance (XAR101 = 100%) is 
assumed for modelling CAPIC-Na formation in R-101.
2.3.1.2 Reactor R-102
A conversion of CAPIC-Na to CYCLOR of 82.5% is reported for a R-102 operating temperature of 
TR102 = 65 °C and an estimated residence time of τ = 2 hr.10 The operating temperature of R-102 is 
chosen to be the same as in the published experimental demonstration (TR102 = 65 °C); thus, the same 
reaction performance (XAR102 = 82.5%) and residence time (τ = 2 hr) are assumed the same reaction 
performance is assumed for modelling the CYCLOR formation in R-102.
2.3.1.3 Reactor R-103
Temperature-dependent kinetic data for API formation in R-103 is available in the literature;10 at 
temperatures of 120, 140 and 165 °C, CYCLOR conversions to API of 10, 60 and 96% are attainable, 
respectively, each for an estimated residence time of 21 min.10 The packed bed reactor (PBR) design 
equation is provided in eq. 2.
τR103 =  CA,0∫
XA
0
dXA
–rA
(2)
Here, τR103 is the residence time of R-103, CA,0 is the concentration of limiting reagent (CYCLOR) 
and rA is the rate of reaction of limiting reagent. The limiting reagent is CYCLOR as NaH in the packed 
bed is in significant excess and so it is assumed that the reaction is first-order in CYCLOR. Following 
this assumption, the first-order rate constant, k, at different temperatures can be estimated. This allows 
the regression of Arrhenius law (eq. 3) parameters, the pre-exponential factor, A, and activation energy, 
Ea, for API formation in R-103, allowing the explicit modelling of CYCLOR conversion to API as a 
function of temperature, T
 k(T) =  Aexp (–EaRT) (3)
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6where R is the universal gas constant. The Arrhenius plot from the available kinetic data is shown in 
Fig. 6 with good fit (coefficient of determination, R2 > 0.96); regressed parameters are Ea = 1.565 kJ 
mol-1 and A = 8.49×1013, assuming R-103 is first-order in CYCLOR. Availability of a wider kinetic 
dataset will allow further validation of Arrhenius parameter estimation results and investigation of more 
complex candidate rate law expressions.
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
2.25 2.35 2.45 2.55
ln
(k
)
103∙TR103-1 (K-1)
R2 = 0.9662
Figure 6: Arrhenius plot for ring closure in the API continuous flow synthesis.
2.3.2 Crystallisation Process
The batch crystallisation yield has a reported yield of 96% in a residence time of 1 hr operating at 25 
°C and pHCRYST = 7.10 Here, we compare the conceptual steady-state continuous crystallisation (CPM) 
to the demonstrated batch (BX) process by varying the pH of the continuous crystallisation. Table 3 
summarises fixed processing conditions for both batch and continuous crystallisation process designs.
Table 3: Summary of fixed process conditions for batch and continuous crystallisation process models.
Batch (BX) Continuous (CPM)
Temperature (°C) 25 25
Thermodynamic efficiency (%) 100 70
τ (hr) 1 0.5
Feed pH ≈ 0.5 ≈ 0.5
Operating pH, pHCRYST 7 Variable
Yield, Y (%) 96 Y = f (pHCRYST)
Crystallisation process design requires modelling of API solubility in process mixtures. The mixture 
prior to pH increase for API crystallisation is predominantly aqueous (solvent content >96 mol% H2O), 
thus the mixture is assumed to be purely aqueous for crystallisation modelling purposes. The aqueous 
solubility, S, of nevirapine in the crystallisation stage (see Fig. 5) as a function of pH is modelled by38
S = S0(1 + 10pKa–pH) (4)
where S0 = 4.58×10-2 g L-1 (solubility under non-ionising conditions) and pKa = 2.8 at 25 °C;38 
correlation parameter values (S0 and pKa) are only available at 25 °C, thus additional temperatures for 
cooling crystallisation modelling cannot be considered. The modelled aqueous API solubility as a 
function of pH is shown with experimental values as reported by various literature references in Fig. 7, 
showing good agreement with experimental values.38,40,41 
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Figure 7: Aqueous API solubility model = f (pH) with experimental values.38,40,41
The crystallisation yield (eq. 5) is estimated from the API concentration in the mother liquor, CCRYST, 
and the aqueous API solubility, S. 
Y =  1 – CCRYST
S
(5)
Both batch and continuous crystallisation processes’ feed streams enter at pH ≈ 0.5. A residence time 
of 0.5 hr is assumed for the continuous crystallisation, chosen to be lower than that of the batch 
crystallisation to reflect the difference in residence times typical of these different operation modes.  It 
is assumed that the batch crystallisation attains full (100%) thermodynamic equilibrium. A conservative 
thermodynamic efficiency of 70% is assumed for the continuous crystallisation to account for 
uncertainty in the assumed residence time and the calculated yield. This will likely result in an under-
prediction of continuous crystallisation yield and thus an over-estimation of total costs, which should 
be considered when interpreting the optimisation results presented here. Provision of detailed 
crystallisation kinetics for nevirapine as well as dynamic and steady-state crystallisation models for 
batch and continuous crystallisation processes, respectively, will provide more detailed process design 
results and insight into the comparative evaluation of batch vs. continuous crystallisation for nevirapine. 
2.4 Process Material Efficiencies
Quantities of waste produced by different designs are compared via the popular green chemistry metric, 
the environmental (E)-factor (eq. 6), defined as the mass ratio of waste to desired product, i.e., recovered 
API.42,43 Here, mwaste is the total mass of waste, mAPI and muAPI are the mass of recovered and unrecovered 
API, respectively, muS is the mass of unrecovered solvent and mur is the mass of unreacted reagents.
E =  
mwaste
mAPI
 =  
muAPI +  muS +  mur
mAPI
(6)
2.5 Costing Methodology
2.5.1 Capital Expenditure (CapEx)
We implement an established methodology for costing pharmaceutical manufacturing processes.5 All 
plant designs are assumed to be constructed and operated at an existing pharmaceutical manufacturing 
site with essential auxiliary structures already in place. Annual operation of 8,000 hours is considered. 
Prices for equipment of similar capacities to those considered here have been sourced where possible; 
where such data is unavailable, the following cost-capacity correlation is used.44
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8PB =  f PA(SBSA)n (7)
Pj is the equipment purchase cost at capacity Sj. Parameters n and f are equipment-dependent and found 
in the literature.45 Where the reference purchase cost (PA) is taken from the past, chemical engineering 
plant cost indices (CEPCIs) are used to calculate the corresponding purchase cost in the year 2018. All 
equipment capacities are scaled to account for plantwide inefficiencies and to meet the specified plant 
capacity. Unit costs and parameter values for f and n (eq. 7) are given in previous work.5,46 Unit 
operations similar to those implemented in the demonstrated continuous flow synthesis10 were 
implemented and scaled and costed using published eq. 7 parameters.45 Table 4 gives details for the 
purchase costs and scaling parameters in eq. 20 for each equipment item.
Table 4: Parameters for scaled equipment purchase costs (eq. 7).45
Item Ref. Year Ref. Cost, PA
(GBP)
Capacity Basis Ref. Capacity, SA n f
(%)
R-101 2007    29,259 Volume (m3) 3.00 0.53 10.33
R-102 2007    29,259 Volume (m3) 3.00 0.53 10.33
R-103 2007 273,079 Volume (m3) 3.00 0.68 10.33
Pump 2015        958 - - - -
Cooler 2015     3,454 - - - -
Mixer 2007   22,230 Power (kW) 5 0.30 10.33
Crystalliser 2007 328,875 Volume (m3) 10 0.22 10.33
The sum of all inflation-adjusted equipment costs (PB) gives the Free-on-Board (FOB) cost. The 
Chilton method is used to calculate the battery limits installed cost (BLIC).44 The installed equipment 
cost (IEC), process piping and instrumentation (PPI) and total physical plant cost (TPPC) are calculated 
from eqs. 8–10. A construction factor of 30% is added to the TPPC to calculate the BLIC (eq. 11).
IEC = 1.43FOB (8)
PPI = 0.42IEC (9)
TPPC = IEC + PPI (10)
BLIC = 1.3TPPC (11)
Working capital (WC) costs are taken as 35% and 3.5% of annual material costs scaled to meet the 
desired plant capacity (MATannual) for batch and continuous processes, respectively (eq. 11). 
Contingency costs (CC) are calculated as 20% of the BLIC (eq. 13). The sum of BLIC, WC and CC 
gives the total capital expenditure (CapEx, eq. 14).
WC = { 0.350MATannual , batch 0.035MATannual  , CPM (12)
CC = 0.2BLIC (13)
CapEx = BLIC + WC + CC (14)
2.5.2 Operating Expenditure (OpEx)
Required material prices are summarised in Table 5. Base case prices for starting materials CAPIC and 
MeCAN are assumed in this work. Current lab-scale demonstrations of batch syntheses of these starting 
materials estimate prices of CAPIC and MeCAN to be higher;10 however, these estimations are made 
from batch synthesis material requirements using reagent grade materials. Given the larger scales of 
operation considered in this work, it can be assumed that material prices will be lower. The annual 
utilities cost (UTILannual) is calculated as 0.96 GBP kg-1 of process material throughput (mprocess) + the 
utilities costs for heating R-103. The heating duty for R-103 is assumed to be the sensible heat required 
to heat the process stream from TR102 = 65 °C to TR103, assuming a heat loss of 20% and an electricity 
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9cost of 13.86 p kWh-1; assuming heat loss of 20% is a rather high estimate for the process scales 
considered here, thus over-estimates in utilities cost values may be present. The annual waste cost 
(Wasteannual) is 0.35 GBP L-1 of waste (Qwaste). Annual operating expenditure (OpExannual) is the sum of 
annual material, utilities and waste costs.
UTILannual = 0.96mprocess + 0.1386QR103 (15)
Wasteannual = 0.35Qwaste (16)
OpExannual = MATannual + UTILannual + Wasteannual (17)
Table 5: Material prices for reagents and components used in continuous API synthesis and crystallisation.
Type Material Price (GBP kg-1) Type Material Price (GBP kg-1)
Synthesis CAPIC
Diglyme
5.00
3.00
Crystallisation AC 1.50
HCl (aq.) 0.50
MeCAN 10.00 NaOH (aq.) 0.25
NaH 5.00
2.5.3 Total Costs
The total cost of the plant designs is calculated as the sum of CapEx and the sum of inflation-adjusted 
OpExannual over the plant lifetime (eq. 18).
 Total Cost =  CapEx +  
t =  20
∑
j =  1
OpExannual(1 +  y) j (18)
A plant-operating lifetime of t = 20 yr and an interest rate of y = 5% are considered. All CapEx is 
assumed to occur in year 0 and operation is assumed to begin in year 1. Annual operation of 8,000 hours 
per year is assumed for consistency with our previously published work in this field. The assumed 
annual operation time can easily be altered to account for varying asset utilisation efficiencies in the 
presented modelling framework by an expert reader.
2.6 Nonlinear Optimisation Formulation
The objective of the optimisation problem is to minimise plantwide total costs (eq. 19). The continuous 
decision variables are the operating temperature of R-103, TR103, and crystallisation pH, pHCRYST, both 
of which influence the final API yield by influencing R-103 conversion to API and crystallisation yield, 
respectively. While increasing TR103 enhances the conversion of CYCLOR to API, there are associated 
utilities costs with heating R-103 (eq. 15), which contribute to OpEx and plant total costs. Similarly, 
while increasing pHCRYST, the crystallisation pH increases, but also incurs higher material costs as well 
as larger crystallisation capacities, which contribute to total costs. 
Constraints on R-103 operating temperature are chosen to be the lower and upper bounds of available 
temperature data for Arrhenius parameter estimation (120 and 165 °C, respectively) to ensure validity 
of the regressed parameters for subsequent modelling and optimisation (eq. 20). Constraints on 
crystallisation pH (eq. 21) were chosen to be from pHCRYST = 1 (close to feed mixture point, pH ≈ 0.5) 
and pH = 7 (the BX crystallisation pH).
min Total Cost (19)
s.t.
120 °C ≤ TR103 ≤ 165 °C (20)
1 ≤ pHCRYST ≤ 7 (21)
The optimisation problem is solved in MATLAB using the interior-point algorithm with tolerances 
of 10-6. Plant capacities of QAPI = {102, 103} kg API yr-1 are investigated to represent small-/pilot-scale 
designs and to be consistent with our previous publications.5,46–48 The effect of solvent recovery, SR, is 
also considered, as this has a significant effect on material consumption, and thus material cost 
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contributions towards OpEx. A reported solvent recovery of 80% is reported in the literature;10 the 
attainable SR may be lower in practice; lower values of 0 and 40% are also considered in this work. 
The nonlinear optimisation problem was solved for all individual combinations of plant capacity, 
QAPI = {102, 103} kg API yr-1 and assumed solvent recovery, SR = {0, 40, 80}%, i.e. six problem 
instances, to avoid mixed integer problem formulations and reduce optimisation problem complexity. 
Multiple initial values for decision variables are tested to ensure a unique optimal solution for each 
problem instance. Initial values of decision variable for each problem instance are R-103 temperature, 
TR103,0 = {130, 145, 160} °C and crystallisation pH, pHCRYST,0 = {2, 4, 6}, i.e. a total of nine initial points 
per problem instance. Unique solutions were attained for all problem instances for different decision 
variable initial values. Solution times were short for all problem instances (Table 6).
Table 6: Optimisation problem solution time for different problem instances.
QAPI (kg API yr-1) SR (%) Solution time (s)
  0 14.5
40 19.5102
80   7.8
  0   8.7
40   7.5103
80   7.4
3. Results and Discussion
3.1 Total Cost Response Surfaces and Optimal Operating Conditions
Cost response surfaces under different design assumptions were generated (presented in Fig. 8) to 
investigate the design space and to ensure that multiple cost minima are not present. Cost response 
surfaces for all design cases show a sharp peak (i.e. very high total costs) at low R-103 operating 
temperature TR103 and low crystallisation pH (pHCRYST). Under these conditions, very low API recovery 
is attained and thus higher material requirements and unit operation capacities are required to meet the 
desired plant capacity (QAPI), resulting in high CapEx and OpEx. At higher capacity (QAPI), response 
surfaces take a similar shape but present higher total cost values due to the increased material throughput 
and correspondingly larger unit operation scales. Varying solvent recovery is also shown to significantly 
affect the cost response surfaces due to its effect on solvent requirements, which is a major contributor 
to the mixture composition and thus on OpEx components, as well as waste.
Optimal decision variables (R-103 operating temperature, TR103, crystallisation pH, pHCRYST) 
corresponding to minimum total costs under different design assumptions are shown in Fig. 9. These 
optima are compared to the process implementing a batch (BX) crystallisation where TR103 = 165 °C 
and pHCRYST = 7). In all BX and CPM design cases, TR103 is at the upper bound of 165 °C. The optimum 
crystallisation pH varies across different CPM design assumptions. At lower solvent recovery (SR = 
0%), optimum pH ≈ 4 is observed for both considered capacities; at low SR, OpEx components are 
significant contributors to total costs and thus higher crystallisation yields are preferred to lower total 
costs. For higher SR = {40, 80}%, pH is driven to the lower bound of 1; the effect of enhancing 
crystallisation yield by increasing pHCRYST is not as important when significant solvent is recovered and 
TR103 is high. At higher capacity (QAPI = 103 kg API yr-1), higher solvent recovery is required to allow a 
lower pH at cost optima. In industrial practice, it may be necessary to neutralise the mixture following 
crystallisation and API crystal removal for safety purposes, however this is not considered as part of 
the presented analysis.
The effect of R-103 operating temperature (TR103) on total costs is significant; total costs decrease 
rapidly as TR103 increases from 125 to 165 °C (Fig. 8). Operating temperature in R-103 significantly 
affects the conversion of CYCLOR to API, thus plantwide API yield is very sensitive to TR103; expensive 
reagents, especially starting materials CAPIC and MeCAN, make materials costs a major contributor 
to total costs and so a high API yield in R-103 (i.e. high TR103) is preferred. The effect of each decision 
variable (TR103 and pHCRYST) on plantwide API yield is shown in Fig. 10 to illustrate this point. The 
optimisation problem formulation in this work could alternatively be defined to maximise net present 
value (NPV), which may yield different results. However, problem formulation for NPV maximisation 
requires the estimation of product sales revenues, which will vary with design assumption (see section 
3.3 for estimated API cost of goods for different plant designs). For this reason, the objective is instead 
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to minimise plant total costs. Comparison of results for a different objective function formulation could 
be useful, given the availability of reliable projected API and brand sales prices.
The effect of operating crystallisation pH (pHCRYST) on total costs is also similar across different 
design assumptions (Fig. 8). At the lower bound of R-103 operating temperature (TR103 = 125 °C), low 
pH (e.g., at the lower bound of pHCRYST = 1) results in high total costs. At low TR103, the low conversion 
of CYCLOR to API in R-103 means plantwide yield is already poor prior to crystallisation; low pHCRYST 
implies lower crystallisation yield and thus higher total costs are incurred due to increased material 
requirements and unit operation scales needed to meet the desired plant capacity (QAPI). The 
implemented model of aqueous API solubility vs. pH (eq. 4, Fig. 7) shows a plateau in solubility beyond 
some pH value below 7. Increasing the crystallisation pH too high will result in incremental increases 
in API yield at best (as shown in Fig. 10) which will unnecessarily increase material usage and 
crystallisation volumes, and thus total costs (as observed in the cost response surfaces in Fig. 8). At the 
upper bound of R-103 operating temperature (TR103 = 165 °C), the effect of crystallisation pH is not so 
significant. The yield of API is already high when TR103 is higher (due to increased conversion of 
CYCLOR to API in R-103) and thus the effect of higher pH in the crystallisation is not so important. 
This point is also further illustrated by the plantwide API yield response surface in Fig. 10.
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Figure 8: Total cost response surfaces for nevirapine CPM under different design assumption of plant 
capacity (QAPI) and solvent recovery (SR).
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Figure 9: Optimal operating (decision) variables corresponding to total cost minima under different 
design assumptions.
The current work only optimises the process implementing a continuous crystallisation (CPM) and 
does not optimise the batch (BX) process. Optimisation of the batch process with respect to decision 
variables considered here (TR103 and pHCRYST) as well as batch scheduling and numbering can allow a 
fairer comparison to CPM designs and should be implemented in future work.49 Furthermore, 
implementation of Process Analytical Technology (PAT) is essential for the success of CPM 
technologies and ensuring operating (decision) variables do not deviate from their optimal values to 
ensure minimum total costs, with recent studies have illustrating the importance of PAT in 
crystallisation applications.50
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Figure 10: Response surface of plantwide API yield vs. R-103 operating temperature (TR103) and 
crystallisation pH (pHCRYST).
3.3 Material Efficiencies
Material efficiencies of different design assumptions quantified by the E-factor (eq. 5) are shown in 
Fig. 11. For all batch designs, E-factor values are very high, even for pharmaceutical processing which 
is renowned for having highly materially intensive manufacturing routes;51 this is due to all batch 
crystallisation processes being operating at pHCRYST = 7, requiring significant quantities of base to 
neutralise the feed mixture. In all cases, increasing solvent recovery significantly reduces E-factor due 
to the large contribution of solvent to process mixture and waste compositions. For pharmaceutical 
manufacturing, the E-factor can be as high as 200; all CPM designs achieve values lower than this, but 
only higher solvent recoveries allow this for the process with a batch crystallisation. Elucidation of 
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attainable solvent recoveries at different production scales will further clarify the likely material 
efficiencies of different design assumptions to elucidate materially efficient CPM plant designs.
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Figure 11: Environmental (E)-factors at cost optima for different design assumptions.
3.4 Total Cost Components and API Cost of Goods
Minimum total cost components for CPM are compared the process with the BX crystallisation are 
compared in Fig. 12 (see also Appendix A, Table A1). Total costs at QAPI = 103 kg API yr-1 are higher, 
reflecting the increased material requirements and unit operation scales. OpEx components are more 
significant than CapEx in all design cases due to the expensive reagents required for the API synthesis. 
As solvent recovery increases, OpEx components decrease significantly and substantially lower total 
costs. Utilities and waste components are the most significantly affected by varying solvent recovery 
due to the large quantity of solvent in the process mixture; materials costs are less affected by varying 
solvent recovery as the reagents used are much more expensive than solvent components in the 
considered process (see Table 2). In all cases, CPM designs have significantly lower OpEx components 
than for BX designs due to the reduced material requirements of the crystallisation process when 
operating at lower pH. The costing methodology implemented here does not include labour 
requirements, which are location- and scale-dependent; elucidation of labour costs will further inform 
process development.
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Figure 12: Total cost components for different design assumptions.
For varying solvent recovery assumptions, CapEx components remain roughly the same, as internal 
process stream flowrates through each unit operation remain fairly consistent. In all cases, CPM designs 
have lower CapEx components than their BX counterparts due to the lower material throughputs of 
these processes. The availability of detailed crystallisation kinetic models with experimental data and 
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model parameters can further elucidate crystallisation process performance and unit operation design, 
which will likely have a significant effect on CapEx. The equipment cost correlation used here (eq. 7) 
is the most widely implemented and reliable available in the peer-reviewed literature; design capacities 
required for the considered plant capacities (QAPI) are at the lower end of the cost correlation application 
range, and thus purchase cost overestimation may be present. Additional uncertainty in calculated unit 
purchase costs is present due to the lack of cost estimation methods for specific equipment; however, 
the cost correlation used here is the best available in the literature. The correlation is the most widely 
implemented in the literature for scaling equipment purchase costs vs. capacity for different types of 
chemical engineering unit operations. Some specialised unit operations have specific cost correlations 
established,52 which may be more accurate than the general correlation used in this work. Cost 
correlations specific to particular unit operations should be used where possible to allow accurate 
prediction of CapEx component contributions to total costs. Furthermore, the considered processes 
(both BX and CPM) are considered to take advantage of being constructed at an existing pharmaceutical 
manufacturing site; additional costs may also be incurred if green-field construction is required.
The starting materials (CAPIC and MeCAN) for the continuous synthesis of nevirapine considered 
in this work are advanced compounds synthesised from multistep batch processes.10 Consideration of 
key material price fluctuations is an important form of sensitivity analysis that should be implemented 
in modelling and economic evaluation during candidate process screening and development stages.5 
Here, we consider the effect of increasing CAPIC and MeCAN material prices by 50% from the base 
case values (Table 2) on plant total costs, i.e. CAPIC price = [5,10] GBP kg-1, MeCAN price = [10,20] 
GBP kg-1, at discrete values of decision variables, TR103 = {130, 145, 160} °C and pHCRYST = {2, 4, 6} 
for QAPI = 102 kg API yr-1 and SR = 40%; observed trends are expected to be the same for alternative 
values of QAPI and SR. The effects of varying material prices for these discrete decision variable values 
are shown in Fig. 13. Although starting material prices do affect total plant costs in all design cases, the 
effect of TR103 is still the most sensitive parameter affecting total costs. Further process intensification 
for the batchwise syntheses of CAPIC and MeCAN will ensure reasonable material prices to ensure the 
economic viability of the process designs investigated here.
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Figure 13: Effect of starting material prices and TR103 and pHCRYST on plant total costs (QAPI = 102 kg 
API yr-1, SR = 40%).
3.5 API Cost of Goods
In all cases, CPM designs are more economically-viable than those implementing a BX crystallisation. 
Cost component savings for each process with respect to the corresponding BX design is shown in 
Table A1 (Appendix A). The most significant savings are realised in OpEx components (materials, 
utilities and waste components, as described in the costing methodology), which allow significant total 
savings due to their large contribution to plant total costs. Ensuring affordable, accessible HIV 
medicines is essential; HIV drug unit prices have varied widely in previous years, so quantifying 
attainable price per unit mass is an important consideration for HIV drug manufacturing.53 The cost of 
goods (CoG) of API is calculated to quantitatively compare differences in affordability of nevirapine 
under different design assumptions. The CoG is calculated as the total mass of API produced during the 
plant lifetime divided by the total cost of constructing and operating the plant. 
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CoG  =  QAPIt
Total Costs
(22)
The resulting API CoG values under different design assumptions are presented in Fig. 14. For all 
cases, CPM designs allow lower API CoG than their batch (BX) alternatives due to the significant total 
cost savings allowed by continuous operation. Solvent recovery has a significant effect on the resulting 
CoG due to the large contribution of solvent to OpEx components, which dominate total costs of all 
design cases. While this analysis does not clarify exactly what price the API will be sold at, the 
estimated CoG values indicate that CPM implementation can allow for lower API sales prices to expand 
global access to this societally-important HIV drug.
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Figure 14: Estimated API cost of goods from total costs of different plant designs.
4. Conclusions
This paper presents the formulation and solution of a nonlinear optimisation problem54 for the total cost 
minimisation of plantwide CPM of nevirapine, a societally important API for HIV-1 treatment. 
Optimisation of a conceptual continuous crystallisation for the purification of the API synthesis effluent 
following the continuous flow synthesis under various design assumptions (plant capacity and solvent 
recovery) are used to quantitatively evaluate different designs for atropine CPM. The operating 
temperature of the final reactor R-103 (TR103) is driven to the upper bound in all design cases to 
maximise API synthesis yield while crystallisation pH (pHCRYST) is always lower than that of the batch 
crystallisation (pH = 7) for CPM designs to minimise major OpEx contributions to plant total costs. In 
all design cases, CPM designs achieve lower total cost components, improved material efficiencies and 
lower API CoG values, demonstrating the promise of CPM over batch for nevirapine production and 
improving global, affordable access to HIV APIs. This work also demonstrates the value of conducting 
technoeconomic optimisation studies towards the development of continuous processes in pursuit of 
economically viable end-to-end CPM plants.
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Appendix A: Total cost components and cost savings
Table A1 details total cost optima component values for both BX and CPM designs and CPM savings 
with respect to BX crystallisation implementation. 
Table A1: Total cost components (106 GBP) and CPM savings with respect to BX (%).
QAPI = 102 kg API yr-1
SR = 0% SR = 40% SR = 80%
BX CPM Savings BX CPM Savings BX CPM Savings
BLIC 0.183 0.159 –13.52 0.183 0.157 –14.64 0.183 0.157 –14.64
WCC 0.048 0.032 –32.76 0.046 0.032 –32.06 0.045 0.031 –30.32
CapEx 0.231 0.191 –17.49 0.230 0.188 –18.16 0.229 0.188 –17.74
Materials 0.632 0.214 –66.18 0.557 0.134 –75.98 0.483 0.079 –83.60
Utilities 0.516 0.175 –66.03 0.318 0.096 –69.94 0.120 0.037 –69.61
Waste 0.189 0.064 –66.03 0.116 0.035 –69.94 0.044 0.013 –69.61
OpEx 1.336 0.453 –66.10 0.992 0.264 –73.33 0.647 0.129 –80.05
Total Costs 1.567 0.644 –58.93 1.221 0.453 –62.95 0.876 0.317 –63.78
QAPI = 103 kg API yr-1
SR = 0% SR = 40% SR = 80%
BX CPM Savings BX CPM Savings BX CPM Savings
BLIC 0.320 0.235 –26.51 0.320 0.235 –26.58 0.320 0.229 –28.46
WCC 0.174 0.051 –70.95 0.161 0.050 –69.31 0.148 0.047 –68.25
CapEx 0.494 0.286 –42.20 0.481 0.284 –40.92 0.468 0.276 –41.08
Materials 6.316 2.109 –66.62 5.573 1.491 –73.24 4.830 0.792 –83.60
Utilities 5.160 1.730 –66.47 3.181 1.065 –66.51 1.202 0.365 –69.61
Waste 1.886 0.632 –66.47 1.162 0.389 –66.50 0.438 0.133 –69.61
OpEx 13.362 4.471 –66.54 9.916 2.946 –70.29 6.470 1.291 –80.05
Total Costs 13.856 4.757 –65.67 10.397 3.230 –68.93 6.939 1.567 –77.42
Nomenclature and Acronyms
Acronyms
API Active pharmaceutical ingredient
BX Batch
CEPCI Chemical engineering plant cost index
CPM Continuous pharmaceutical manufacturing
HIV Human immunodeficiency virus
LLE Liquid-liquid extraction
NPV Net present value
PAT Process analytical technology
PBR Packed bed reactor
WHO World Health Organisation
Variables
Latin Letters
A Pre-exponential factor
BLIC Battery limits installed costs (GBP)
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CCRYST Concentration of API in the crystallisation mother liquor (g L-1)
Ci,0 Initial concentration of reagent i (M)
CapEx Capital expenditure (GBP)
CC Contingency costs (GBP)
CoG Cost of goods (GBP kg-1)
E Environmental (E)-factor
Ea Activation energy (J mol-1)
f Correction factor in eq. 7
FA,0j Molar flowrate of limiting reagent A entering reactor j (mol s-1)
Fij Molar flowrate of component i exiting reactor j (mol s-1)
FOB Free-on-Board Costs (GBP)
IEC Installed equipment costs (GBP)
k 1st-order reaction rate constant of R-103 (s-1)
mAPI Mass of recovered API (kg yr-1)
mprocess Plant material throughput (kg yr-1)
mur Mass of reagents remaining in waste streams (kg yr-1)
muAPI Mass of unrecovered API (kg yr-1)
muS Mass of unrecovered solvent (kg yr-1)
mwaste Mass of waste (kg yr-1)
MATannual Annual material costs (GBP yr-1)
n Exponent in eq. 7
OpExannual Annual operating expenditure (GBP yr-1)
Pj Equipment purchase cost at capacity j (GBP)
pHCRYST Crystallisation pH
pHCRYST,0 Initial value of crystallisation pH in problem formulation
PPI Process piping and instrumentation costs (GBP)
QAPI Plant API capacity (kg API yr-1)
QR103 Heating duty of R-103 considering 20% heat loss
Qwaste Volumetric flow of waste output (L yr-1)
R Universal gas constant (8.314 J mol-1 K-1)
R2 Coefficient of determination
S Aqueous API solubility (g L-1)
Sj Capacity of equipment j (varying units)
S0 Non-ionised aqueous API solubility (g L-1)
SR Solvent recovery (%)
Ti Operating temperature of reactor i (°C)
TR103,0 Initial value of R-103 operating temperature (°C) in problem formulation
t Plant operation lifetime (yr)
TPPC Total physical plant cost (GBP)
UTILannual Annual utilities costs (GBP yr-1)
Vj Volume of unit j (m3)
Wasteannual Annual waste disposal cost (GBP yr-1)
WC Working capital costs (GBP)
XAj Conversion of limiting reagent in reactor j (%)
Y Crystallisation yield (%)
y Interest rate (%)
Greek Letters
Θij Molar ratio of excess reagent i to limiting reagent in reactor j
νij Stoichiometric coefficient of reagent i in reactor j
τ Residence time (s)
Molecules and Reagents
2-CAN 2-(cyclopropylamino)nicotinic acid
AC Activated carbon
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Ac2O Acetic anhydride
Al2O3 Aluminium oxide
API Active pharmaceutical ingredient (Nevirapine)
CAPIC 2-chloro-3-amino-4-picoline
CAPIC-Na CAPIC sodium salt
COMAD 2-chloro-4-methylnicotinamide
CPA Cyclopropylamine
CYCIC 2-chloro-4-methylnicotinonitrile
CYCLOR N-(2-chloro-4-methylpyridin-3-yl)-2-(cyclopropylamino)nicotinamide
DMF-DMS Dimethyl formamide-dimethyl sulphate
H2SO4 Sulphuric acid
HCl Hydrogen chloride
IPA Isopropyl alcohol
KOH Potassium hydroxide
MeCAN 2-(cyclopropylamino)nicotinate
MeOH Methanol
Mg2SO4 Magnesium sulphate
NaH Sodium hydride
NaOBr Sodium hypobromite
NaOH Sodium hydroxide
PhMe Toluene
SOCl2 Thionyl chloride
TEA Triethylamine
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